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Introduction
Clinical studies on the elimination of amphotericin B
(AMB) lipid formulations in liver failure have been lack-
ing so far. Therefore, the pharmacokinetics of AMB colloi-
dal dispersion (ABCD) was assessed in critically ill
patients with cholestatic liver failure.
Patients and methods
Time-concentration profiles were determined in critically
ill patients with cholestatic liver failure and in critically ill
patients with normal hepatic function requiring ABCD for
invasive fungal infections. Lipid-associated and liberated
AMB were separated by solid phase extraction and quanti-
fied by high performance liquid chromatography.
Results
Three patients with impaired and two patients with nor-
mal hepatic function (one patient on day 1, one patient
on day 5 of therapy) were enrolled so far. After a single
dose of ABCD, the AMB half life was similar in patients
with impaired and normal liver function. The AMB clear-
ance was slower in liver failure (0.15 vs. 0.54 L/h/kg for
total AMB, 0.22 vs. 0.55 L/h/kg for the liberated AMB frac-
tion and 0.52 vs. 35.6 L/kg for lipid-associated AMB) and
the apparent volume of distribution was smaller (2.2 vs.
10.9 L/kg for total AMB, 3.1 vs. 11.2 L/kg for liberated and
8.2 vs. 154.5 L/h/kg for lipid-associated AMB).
Conclusion
The elimination of ABCD appears to be delayed in chole-
static liver failure. More pharmacokinetic data are
required to establish reliable dose recommendations for
ABCD in patients with liver failure.
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